Chronic Kidney Disease

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing patient engagement and treatment outcomes.

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney disease (CKD), highlighting its dual-action benefits.

Race-free kidney function equations may underestimate risks for Black adults according to a new analysis.

A recent study reveals that many patients start dialysis at low-quality facilities due to convenience, highlighting significant racial disparities in care access.

Women, older adults, and low-income countries are impacted most; researchers call for urgent public health interventions.

While multiple machine learning (ML) algorithms offered similar predictive performance, the cost-effective analysis revealed stark differences in the costs associated with their use.

Recent research reveals COVID-19 significantly increases long-term kidney dysfunction risk compared with influenza, especially in older adults and men.

Childhood cancer survivors face heightened risks of chronic kidney disease and hypertension, necessitating urgent updates to monitoring guidelines for their long-term health.

New research reveals how serum soluble Klotho levels relate to chronic kidney disease risk (CKD) in patients with diabetes and hypertension.

The findings highlight important differences between therapies in managing blood glucose, blood pressure, lipids, and adverse effects in this high-risk patient population.

An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.

This week, the Center on Health Equity & Access covered artificial intelligence, diabetes clinical trials, racial disparities in cancer antigen thresholds, and more.

Initiating chronic kidney disease (CKD) screening at age 55 yielded substantial reductions in kidney failure incidence and improvements in life expectancy across all groups.

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.

A series of new studies from the National Kidney Foundation Spring Clinical Meeting exhibit the association between impaired kidney function and prolonged hospital stays, higher charges, and greater resource utilization.

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary immunoglobulin A (IgA) nephropathy.

Non-Hispanic Black populations face the highest risk of death from chronic kidney disease (CKD)–associated cardiac arrest, a study found.

Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).

The Kidney Disease: Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney disease (CKD) management.

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which interested investigators in potential links between these weight fluctuations and increased risk of renal events among a population with type 1 diabetes.

The authors observed a significant increase in optimal starts for dialysis and in peritoneal dialysis rates after implementing a standardized end-stage renal disease transition pathway.

Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.

Preventing or delaying the onset of end-stage kidney disease is vital. By implementing a results-driven, value-based approach, Dallas Nephrology Associates has demonstrated improved patient outcomes and value for payers.

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.

Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, speaks to the value of population health strategies in clinical approaches to care delivery for patients with chronic kidney disease (CKD).

Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.

A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology intervention.

Frequency of patient-provider conversations and patient activation are the 2 most significant predictors of a high-risk patient’s behaviors to prevent kidney disease.